Skip to main content

mantle cell lymphoma

From the Field
04/20/2022
Dr Kotchetkov and colleagues assessed the pattern of B-R administration, efficacy and safety in adult patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma with advanced disease and co-morbidities in the real-world setting.
Dr Kotchetkov and colleagues assessed the pattern of B-R administration, efficacy and safety in adult patients with indolent non-Hodgkin lymphoma and mantle cell lymphoma with advanced disease and co-morbidities in the real-world setting.
Dr Kotchetkov and colleagues...
04/20/2022
Journal of Clinical Pathways
Conference Coverage
12/09/2020
Journal of Clinical Pathways
News
06/25/2020
A study presented at the European Hematology Association (EHA) Annual Meeting (June 11-21, 2020) shed light on real-world outcomes in patients with mantle cell lymphoma (MCL) who were treated with rituximab plus...
A study presented at the European Hematology Association (EHA) Annual Meeting (June 11-21, 2020) shed light on real-world outcomes in patients with mantle cell lymphoma (MCL) who were treated with rituximab plus...
A...
06/25/2020
Journal of Clinical Pathways
News
06/18/2020
Patients with high-risk mantle cell lymphoma (MCL) biology—defined by blastoid variance, Ki-67 greater than 30%, or high p53 immunohistochemistry expression—are more likely to experience shorter failure-free and...
Patients with high-risk mantle cell lymphoma (MCL) biology—defined by blastoid variance, Ki-67 greater than 30%, or high p53 immunohistochemistry expression—are more likely to experience shorter failure-free and...
...
06/18/2020
Journal of Clinical Pathways
News
06/11/2020
At the American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-31, 2020), researchers from the North American Mantle Cell Lymphoma (MCL) Consortium offered clinical, biological, and genomic markers that...
At the American Society of Clinical Oncology (ASCO) Annual Meeting (May 29-31, 2020), researchers from the North American Mantle Cell Lymphoma (MCL) Consortium offered clinical, biological, and genomic markers that...
At the...
06/11/2020
Journal of Clinical Pathways
News
05/27/2020
A new study assessed clinical outcomes and predictors of survival in older patients with mantle cell lymphoma (MCL) treated in the rituximab era. Results of the study are to be presented at the American Society of...
A new study assessed clinical outcomes and predictors of survival in older patients with mantle cell lymphoma (MCL) treated in the rituximab era. Results of the study are to be presented at the American Society of...
A new...
05/27/2020
Journal of Clinical Pathways
News
05/20/2020
Researchers recently compared health care resource utilization (HRU) and costs of relapsed or refractory (R/R) mantle cell lymphoma (MCL) patients treated with ibrutinib ± rituximab (I±R) or chemoimmunotherapy (CIT)...
Researchers recently compared health care resource utilization (HRU) and costs of relapsed or refractory (R/R) mantle cell lymphoma (MCL) patients treated with ibrutinib ± rituximab (I±R) or chemoimmunotherapy (CIT)...
...
05/20/2020
Journal of Clinical Pathways
Research in Review
08/21/2017
JCP Editors
Patients with mantle cell lymphoma (MCL) should be stratified based on the status of a specific mutation and considered for alternative first-line therapy, according to a new study published in Blood (online August...
Patients with mantle cell lymphoma (MCL) should be stratified based on the status of a specific mutation and considered for alternative first-line therapy, according to a new study published in Blood (online August...
...
08/21/2017
Journal of Clinical Pathways